Research Notes: SBRT for Lung Cancer

In the past year, a number of studies have continued to add to the library of clinical research detailing the efficacy of stereotactic body radiation therapy (SBRT) for lung cancer. Below are a few highlights of recent findings:

  • In a study completed by Virginia Hospital Center and Georgetown University Hospital, researchers found that combining SBRT with other forms of treatment for non-small cell lung cancer can increase survival outcomes. Read more here.
  • The German Society of Radiation Oncology collected data from nearly 600 non-small cell lung cancer patients who underwent SBRT and found consistently low rates of the spread of tumors thanks in large part to the radiotherapy dosage. Find more details on the study from the International Association for the Study of Lung Cancer.
  • Members of the Japan Clinical Oncology Group (JCOG) found that SBRT for early stage medically inoperable non-small cell lung cancer doubled overall survival rates as compared to conventional radiation treatment. The study examined the safety and efficacy of SBRT for 100 lung cancer patients treated over four years. Results show that patients exhibited minimal toxicity and improved survival rates. Read more at the Radiological Society of North America.

Our center treats patients with SBRT using CyberKnife® technology. For more information on our treatment process view our presentation.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.